Domestic companies are now ready to launch homegrown biosimilars into the global market next year.

According to industry sources on the 28th, Celltrion, Samsung Bioepis, and Dong-A ST have completed Phase III clinical trials of its biosimilars and applied for approval from overseas regulators. The companies have successfully developed biosimilars for their global blockbusters such as Stelara and Prolia and are seeking approval next year.

Celltrion expects to receive approval for 3 biosimilars next year
Celltrion has the largest biosimilar pipeline among domestic companies. To date, the company has 12 pipelines, with six products on the market that include the COVID-19 drug Regk